BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Okamoto K, Mimura K, Murawaki Y, Yuasa I. Association of functional gene polymorphisms of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J Gastroenterol Hepatol 2005;20:1102-8. [PMID: 15955221 DOI: 10.1111/j.1440-1746.2005.03860.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Bauer A, Habior A. Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis. Front Immunol 2022;13:885229. [DOI: 10.3389/fimmu.2022.885229] [Reference Citation Analysis]
2 Vastrad B, Vastrad C. Bioinformatics analysis of differentially expressed genes in non alcoholic fatty liver disease using next generation sequencing data.. [DOI: 10.1101/2021.12.16.472893] [Reference Citation Analysis]
3 Gupta S, Pinky, Vishal, Sharma H, Soni N, Rao EP, Dalela M, Yadav A, Nautiyal N, Kumar A, Nayak B, Banerjee A, Dinda AK, Mohanty S. Comparative Evaluation of Anti-Fibrotic Effect of Tissue Specific Mesenchymal Stem Cells Derived Extracellular Vesicles for the Amelioration of CCl4 Induced Chronic Liver Injury. Stem Cell Rev Rep 2021. [PMID: 34859376 DOI: 10.1007/s12015-021-10313-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Betsou A, Lambropoulou M, Georgakopoulou AE, Kostomitsopoulos N, Konstandi O, Anagnostopoulos K, Tsalikidis C, Simopoulos CE, Valsami G, Tsaroucha AK. The hepatoprotective effect of silibinin after hepatic ischemia/reperfusion in a rat model is confirmed by immunohistochemistry and qRT-PCR. J Pharm Pharmacol 2021:rgab062. [PMID: 33847359 DOI: 10.1093/jpp/rgab062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Shevchenko AV, Prokofyev VF, Konenkov VI, Khapaev RS, Nimaev VV. Polymorphism of vascular endothelial growth factor gene (<i>VEGF</i>) and matrix metalloproteinase (<i>ММР</i>) genes in primary limb lymphedema. Med immunol 2020;22:497-506. [DOI: 10.15789/1563-0625-pov-1913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Geervliet E, Bansal R. Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases. Cells. 2020;9. [PMID: 32414178 DOI: 10.3390/cells9051212] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 13.7] [Reference Citation Analysis]
7 Xie H, Su D, Zhang J, Ji D, Mao J, Hao M, Wang Q, Yu M, Mao C, Lu T. Raw and vinegar processed Curcuma wenyujin regulates hepatic fibrosis via bloking TGF-β/Smad signaling pathways and up-regulation of MMP-2/TIMP-1 ratio. Journal of Ethnopharmacology 2020;246:111768. [DOI: 10.1016/j.jep.2019.01.045] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
8 Al-mozan HD, Mousa HM, Al-badry BJ. Prevalence of cancer disease in Thi_Qar Provence. J Phys : Conf Ser 2019;1294:062039. [DOI: 10.1088/1742-6596/1294/6/062039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Shevchenko AV, Prokofiev VF, Konenkov VI, Klimontov VV, Tyan NV, Chernykh DV, Trunov AN, Chernykh VV. POLYMORPHISMS OF EXTRACELLULAR CONNECTIVE TISSUE REMODELING PROTEINASES AND <i>MMP2, MMP3, MMP9</i> GENES, AND NEOANGIGENESIS <i>VEGF</i> GENE IN RETINAL MICROANGIOPATHY IN THE PATIENTS WITH TYPE 2 DIABETES MELLITUS. Med immunol 2019;21:441-450. [DOI: 10.15789/1563-0625-2019-3-441-450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Prishchepenko VA, Yupatov GI, Okulich VK. The role of the enzyme systems of the organism in the development of chronic liver diseases. Dok gastroenterol 2018;7:35. [DOI: 10.17116/dokgastro20187235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Zhang M, Hu X, Li S, Lu C, Li J, Zong Y, Qi W, Yang H. Hepatoprotective effects of ethyl pyruvate against CCl4-induced hepatic fibrosis via inhibition of TLR4/NF-κB signaling and up-regulation of MMPs/TIMPs ratio. Clin Res Hepatol Gastroenterol 2018;42:72-81. [PMID: 28601590 DOI: 10.1016/j.clinre.2017.04.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
12 Collazos J, Valle-Garay E, Suárez-Zarracina T, Montes AH, Cartón JA, Asensi V. Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients. World J Virol 2017; 6(2): 36-45 [PMID: 28573088 DOI: 10.5501/wjv.v6.i2.36] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
13 Ramos-Lopez O, Martinez-Lopez E, Roman S, Fierro NA, Panduro A. Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico. World J Gastroenterol 2015; 21(41): 11552-11566 [PMID: 26556986 DOI: 10.3748/wjg.v21.i41.11552] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
14 Thompson A, Clark P, Aghemo A. Hepatitis C Virus. Handbook of Pharmacogenomics and Stratified Medicine 2014. [DOI: 10.1016/b978-0-12-386882-4.00037-2] [Reference Citation Analysis]
15 Chaudhary AK, Nadkarni AH, Pandya S, Ghosh K. Matrix Metalloproteinase and Its Inhibitors in Cancer Progression. Role of Proteases in Cellular Dysfunction 2014. [DOI: 10.1007/978-1-4614-9099-9_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Breikaa RM, Algandaby MM, El-Demerdash E, Abdel-Naim AB. Multimechanistic antifibrotic effect of biochanin a in rats: implications of proinflammatory and profibrogenic mediators. PLoS One. 2013;8:e69276. [PMID: 23874933 DOI: 10.1371/journal.pone.0069276] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
17 Holmes JA, Thompson AJ, Adams LA. Biomarkers of Fibrosis and Fibrosis Progression in Chronic Hepatitis C. Curr Hepatitis Rep 2012;11:231-242. [DOI: 10.1007/s11901-012-0148-0] [Reference Citation Analysis]
18 Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012;57:1110-25. [PMID: 22659520 DOI: 10.1016/j.jhep.2012.05.016] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
19 Skorupski P, Jankiewicz K, Miotła P, Marczak M, Kulik-Rechberger B, Rechberger T. The polymorphisms of the MMP-1 and the MMP-3 genes and the risk of pelvic organ prolapse. Int Urogynecol J 2013;24:1033-8. [PMID: 23108733 DOI: 10.1007/s00192-012-1970-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
20 Lương KVQ, Nguyễn LTH. Theoretical basis of a beneficial role for vitamin D in viral hepatitis. World J Gastroenterol 2012; 18(38): 5338-5350 [PMID: 23082050 DOI: 10.3748/wjg.v18.i38.5338] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
21 Yang J, Zheng J, Wu L, Shi M, Zhang H, Wang X, Xia N, Wang D, Liu X, Yao L, Li Y, Dou K. NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats. PLoS One 2011;6:e27710. [PMID: 22110735 DOI: 10.1371/journal.pone.0027710] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
22 Yang J, Zheng J, Wu L, Shi M, Zhang H, Wang X, Xia N, Wang D, Liu X, Yao L. NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats. PLoS One. 2011;6:e27710. [PMID: 22110735 DOI: 10.1371/journal.pone.0027710]] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Chaudhary AK, Pandya S, Mehrotra R, Singh M, Singh M. Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers 2011;16:577-86. [DOI: 10.3109/1354750x.2011.609602] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
24 Juran BD, Atkinson EJ, Schlicht EM, Larson JJ, Ellinghaus D, Franke A, Lazaridis KN. Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis. Liver Int 2011;31:785-91. [PMID: 21134112 DOI: 10.1111/j.1478-3231.2010.02420.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
25 Erbek SS, Yurtcu E, Erbek S, Sahin FI. Matrix metalloproteinase-9 promoter gene polymorphism (-1562C>T) in nasal polyposis. Am J Rhinol Allergy 2009;23:568-70. [PMID: 19958602 DOI: 10.2500/ajra.2009.23.3371] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
26 Fanjul-fernández M, Folgueras AR, Cabrera S, López-otín C. Matrix metalloproteinases: Evolution, gene regulation and functional analysis in mouse models. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2010;1803:3-19. [DOI: 10.1016/j.bbamcr.2009.07.004] [Cited by in Crossref: 359] [Cited by in F6Publishing: 379] [Article Influence: 27.6] [Reference Citation Analysis]
27 Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103:71-83. [PMID: 19914930 DOI: 10.1093/qjmed/hcp158] [Cited by in Crossref: 442] [Cited by in F6Publishing: 472] [Article Influence: 31.6] [Reference Citation Analysis]
28 Laouénan C, Plancoulaine S, Mohamed MK, Arafa N, Bakr I, Abdel-hamid M, Rekacewicz C, Obach D, Fontanet A, Abel L. Evidence for a dominant major gene conferring predisposition to hepatitis C virus infection in endemic conditions. Hum Genet 2009;126:697-705. [DOI: 10.1007/s00439-009-0721-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
29 Minisini R, Fabris C, Toniutto P, Pirisi M. Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infections. Expert Opinion on Medical Diagnostics 2009;3:355-70. [DOI: 10.1517/17530050902893311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Borghaei RC, Gorski G, Javadi M; Mariah Chambers. NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter. Biochem Biophys Res Commun 2009;382:269-73. [PMID: 19275880 DOI: 10.1016/j.bbrc.2009.03.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
31 Checa M, Ruiz V, Montaño M, Velázquez-Cruz R, Selman M, Pardo A. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet 2008;124:465-72. [PMID: 18853190 DOI: 10.1007/s00439-008-0571-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
32 Nho YK, Ha E, Yu KI, Chung JH, Wook NC, Chung IS, Lee MY, Shin DH. Matrix metalloproteinase-1 promoter is associated with body mass index in Korean population with aged greater or equal to 50 years. Clin Chim Acta 2008;396:14-7. [PMID: 18602909 DOI: 10.1016/j.cca.2008.06.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
33 Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134:1699-714. [PMID: 18471548 DOI: 10.1053/j.gastro.2008.02.069] [Cited by in Crossref: 156] [Cited by in F6Publishing: 162] [Article Influence: 10.4] [Reference Citation Analysis]
34 Stickel F, Osterreicher CH, Halangk J, Berg T, Homann N, Hellerbrand C, Patsenker E, Schneider V, Kolb A, Friess H. No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease. Alcohol Clin Exp Res. 2008;32:959-965. [PMID: 18445105 DOI: 10.1111/j.1530-0277.2008.00654.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
35 Xia JR, Liu NF, Zhu NX. Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats. Int J Mol Sci. 2008;9:638-661. [PMID: 19325776 DOI: 10.3390/ijms9040638] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
36 Shin HP, Lee JI, Jung JH, Yim SV, Kim HJ, Cha JM, Park JB, Joo KR, Hwang JS, Jang BK. Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease. Dig Dis Sci 2008;53:823-9. [PMID: 17763953 DOI: 10.1007/s10620-007-9937-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Kuo HP, Wang YM, Wang CH, He CC, Lin SM, Lin HC, Liu CY, Huang KH, Hsieh LL, Huang CD. Matrix metalloproteinase-1 polymorphism in Taiwanese patients with endobronchial tuberculosis. Tuberculosis (Edinb) 2008;88:262-7. [PMID: 17996495 DOI: 10.1016/j.tube.2007.08.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wang H, Zhang Y, Heuckeroth RO. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett. 2007;581:3098-3104. [PMID: 17561000 DOI: 10.1016/j.febslet.2007.05.049] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 3.9] [Reference Citation Analysis]
39 Tu H, Wu C, Kao S, Liu C, Liu T, Lui M. Functional −1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users: Association between MMP-9 functional polymorphism and oral cancer. Journal of Oral Pathology & Medicine 2007;36:409-14. [DOI: 10.1111/j.1600-0714.2007.00552.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 1.9] [Reference Citation Analysis]
40 Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007;46:955-75. [PMID: 17383048 DOI: 10.1016/j.jhep.2007.02.003] [Cited by in Crossref: 345] [Cited by in F6Publishing: 358] [Article Influence: 21.6] [Reference Citation Analysis]
41 Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12(23): 3682-3694 [PMID: 16773685 DOI: 10.3748/wjg.v12.i23.3682] [Cited by in CrossRef: 180] [Cited by in F6Publishing: 188] [Article Influence: 10.6] [Reference Citation Analysis]